influenza
viru
one
common
human
respiratori
virus
affect
gener
popul
immunosuppress
confer
greater
number
complic
howev
prior
emerg
new
influenza
viru
inform
avail
clinic
manifest
prognosi
influenza
solid
organ
transplant
sot
recipi
quit
scarc
pandem
knowledg
influenza
infect
behaviour
transplant
recipi
increas
markedli
highlight
potenti
sever
import
proper
treatment
incid
influenza
respiratori
virus
probabl
underestim
given
low
sensit
diagnost
techniqu
prior
polymeras
chain
reaction
pcr
techniqu
incid
greater
lung
transplant
patient
organ
transplant
infect
viru
may
occur
time
transplant
median
vari
month
howev
studi
shown
also
occur
first
day
transplant
associ
greater
sever
mortal
clinic
manifest
prognosi
clinic
manifest
similar
occur
immunocompet
patient
patient
indic
fever
cough
patient
present
imag
consist
pneumonia
gener
multilobar
involv
laboratori
abnorm
frequent
gener
popul
number
lymphocyt
platelet
significantli
reduc
viral
infect
tabl
influenza
sot
recipi
diseas
consider
associ
morbid
mortal
clearli
higher
immunocompet
patient
studi
perform
proport
patient
requir
hospitalis
vari
one
everi
five
patient
suffer
sever
complic
approxim
die
tabl
delay
hospitalis
initi
treatment
oseltamivir
clearli
associ
mortal
occur
gener
popul
anoth
factor
significantli
sot
recipi
time
initi
treatment
oseltamivir
associ
greater
presenc
complic
icu
admiss
mortal
modifi
prognost
factor
therefor
essenti
high
level
suspicion
influenza
infect
patient
period
epidem
diagnost
possibl
assess
case
pneumonia
even
certain
diagnosi
bacteri
infect
empir
antivir
treatment
initi
earli
possibl
unclear
whether
patient
requir
higher
dose
usual
longer
treatment
time
one
effect
measur
reduc
incid
complic
influenza
annual
vaccin
season
influenza
measur
shown
reduc
mortal
graft
loss
risk
transplant
popul
howev
respons
influenza
vaccin
transplant
popul
gener
lower
gener
popul
highli
variabl
seroprotect
rate
rang
vaccin
respons
depend
type
immunosuppress
viral
strain
involv
administr
rout
use
adjuv
therapi
presenc
baselin
antibodi
titr
time
vaccin
variou
strategi
evalu
improv
immunolog
respons
vaccin
annual
vaccin
booster
shot
intraderm
administr
despit
hypothet
possibl
reject
influenza
vaccin
mediat
immun
respons
vaccin
never
clinic
relev
reject
howev
shown
occur
relat
influenza
infect
due
safeti
factor
effect
potenti
sever
infect
known
reason
delay
vaccin
sixth
month
posttranspl
given
respons
vaccin
optim
transplant
patient
measur
need
taken
prevent
infect
sot
recipi
vaccin
recipi
cohabit
medic
personnel
treat
recipi
recent
year
noteworthi
role
respiratori
virus
recognis
infect
sot
recipi
previous
undervalu
due
limit
microbiolog
method
molecular
techniqu
provid
breakthrough
understand
epidemiolog
clinic
impact
virus
sot
mani
respiratori
virus
may
affect
respiratori
tract
includ
syncyti
respiratori
viru
srv
parainfluenza
piv
adenoviru
adv
certain
emerg
virus
rhinoviru
rv
metapneumoviru
mpv
recent
one
bocaviru
bv
certain
coronavirus
cov
common
respiratori
viru
infect
sot
common
gener
popul
similarli
exhibit
clear
season
although
piv
adv
may
appear
throughout
year
although
infect
mainli
contract
commun
occasion
nosocomi
favour
longer
elimin
viru
acut
phase
immunosuppress
patient
adv
transmiss
tissu
blood
report
reactiv
certain
latent
virus
also
possibl
occur
adv
common
respiratori
virus
may
involv
upper
lower
respiratori
tract
infect
immunocompet
patient
specif
clinic
manifest
specif
viru
therefor
diagnost
strategi
consid
possibl
virus
atyp
present
common
sot
patient
hinder
diagnosi
mani
common
respiratori
viral
infect
sot
patient
mild
selflimit
requir
hospitalis
howev
compar
gener
popul
infect
caus
longer
clinic
condit
greater
risk
progress
lower
respiratori
tract
infect
increas
mortal
also
associ
acut
chronic
reject
although
complic
may
appear
context
type
transplant
frequent
associ
lung
heartlung
transplant
degre
immunosuppress
replic
persist
elimin
viru
month
even
year
also
favour
complic
well
document
piv
srv
rv
coinfect
pathogen
common
may
contribut
increas
morbid
mortal
aetiolog
diagnosi
infect
perform
earli
possibl
especi
earli
posttranspl
period
patient
greater
immunosuppress
epidem
tabl
clinic
outcom
manifest
influenza
solid
organ
transplant
recipi
variabl
valu
import
perform
upper
lower
respiratori
tract
infect
sinc
former
may
promot
onset
pneumonia
microbiolog
studi
perform
respiratori
sampl
use
throat
nasal
swab
properli
collect
insert
special
transport
medium
virus
good
option
complic
bronchoalveolar
lavag
ideal
sampl
sinc
also
allow
studi
aetiolog
agent
diagnosi
perform
use
cell
cultur
antigen
detect
pcr
techniqu
immunosuppress
patient
serolog
use
sinc
result
take
long
immun
respons
may
impair
cell
cultur
refer
techniqu
certain
virus
allow
confirm
viru
viabil
howev
lengthi
labour
intens
methodolog
avail
growth
virus
shell
vial
cultur
incub
time
reduc
hour
sensit
reduc
antigen
detect
techniqu
fast
high
specif
avail
specif
virus
sensit
limit
current
microbiolog
diagnosi
mainli
perform
use
molecular
amplif
method
pcr
techniqu
help
detect
virus
could
studi
otherwis
techniqu
highli
sensit
rapid
simultan
detect
sever
virus
current
realtim
pcr
system
optimis
methodolog
also
help
easili
quantifi
viral
dna
rna
concentr
high
sensit
method
also
drawback
frequent
detect
virus
asymptomat
individu
prolong
detect
virus
patient
alreadi
clinic
recov
undoubtedli
major
challeng
determin
whether
viru
detect
respiratori
tract
caus
respiratori
condit
cultur
techniqu
report
infect
isol
viru
patient
quantif
viru
may
help
interpret
result
sinc
high
viral
load
associ
presenc
symptom
may
relat
sever
clinic
pictur
infecti
process
immunosuppress
reduct
key
element
manag
patient
also
essenti
carri
earli
diagnosi
lead
fastest
possibl
establish
control
measur
avoid
transmiss
provid
appropri
treatment
possibl
data
regard
immunoprophylaxi
sot
specif
monoclon
antibodi
palivizumab
srv
srvigiv
seem
reduc
frequenc
sever
infect
option
treatment
limit
ribavirin
antivir
approv
fda
treatment
respiratori
virus
influenza
use
lower
respiratori
tract
infect
due
srv
piv
mpv
alon
combin
intraven
immunoglobulin
good
result
pleconaril
use
rhinoviru
infect
clinic
situat
although
recommend
transplant
patient
sinc
may
interact
immunosuppress
use
system
interferon
also
recommend
sinc
may
predispos
patient
organ
reject
cidofovir
appear
good
result
adv
infect
although
signific
toxic
limit
use
progress
requir
increas
understand
respiratori
virus
sot
patient
order
accomplish
prospect
multicentr
studi
need
includ
larg
number
patient
along
strict
lengthi
followup
promot
research
new
antivir
cossart
et
al
identifi
new
viral
agent
call
detect
serum
sampl
number
hepat
b
viru
detect
trial
offici
classifi
member
parvovirida
famili
recognis
use
term
associ
clinic
pictur
viral
antigen
detect
serum
paediatr
patient
sickl
cell
anaemia
transient
aplast
crise
two
year
later
associ
erythaema
infectiosum
current
recognis
aetiolog
agent
clinic
pictur
subsequ
vertic
transmiss
report
possibl
caus
miscarriag
develop
foetal
hydrop
well
arthrit
condit
adult
erythroviru
infect
worldwid
distribut
common
evidenc
seropreval
studi
show
percentag
popul
present
antibodi
viru
increas
age
reach
geriatr
popul
viru
transmit
commun
via
respiratori
tract
although
vertic
transmiss
transmiss
blood
product
also
possibl
current
evid
viru
may
persist
acut
infect
hepat
synovi
skin
tissu
although
clinic
signific
find
yet
determin
viru
belong
erythroviru
genu
parvovirida
famili
emerg
bocavirus
member
famili
capabl
caus
diseas
human
structur
viru
simpl
genom
consist
singl
dna
chain
encod
synthesi
nonstructur
protein
two
capsid
protein
lack
envelop
make
highli
resist
inactiv
heat
organ
solvent
three
circul
genotyp
genotyp
common
two
subgroup
genotyp
also
report
associ
found
variou
genotyp
clinic
manifest
caus
viru
erythroviru
infect
suspect
sot
recipi
present
undetermin
chronic
recur
anaemia
pancytopaenia
clinic
manifest
includ
fever
arthralgia
rash
patient
infect
viru
presenc
fever
arthralgia
erythaema
observ
patient
respect
howev
anaemia
present
case
viru
also
involv
aetiolog
agent
clinic
manifest
hepat
myocard
pneumon
neurolog
disord
vascul
also
associ
graft
dysfunct
renal
transplant
although
lack
prospect
studi
includ
larg
number
patient
frequenc
clinic
manifest
attribut
erythroviru
sot
receptor
estim
around
author
suggest
figur
may
higher
first
diagnost
step
determin
igg
igm
antibodi
viru
although
product
antibodi
immunocompromis
patient
may
delay
may
occur
recent
year
genom
amplif
techniqu
use
increas
frequenc
noncommerci
sometim
incap
detect
genotyp
viral
dna
may
detect
prolong
period
acut
infect
therefor
result
interpret
appropri
clinic
context
data
preval
viral
dna
blood
donor
rang
reach
preval
bone
marrow
donor
one
studi
cytolog
examin
bone
marrow
show
find
characterist
viral
infect
specif
antivir
treatment
erythroviru
infect
whenev
possibl
reduc
immunosuppress
consid
intraven
administr
immunoglobulin
shown
benefici
although
optim
treatment
dose
durat
well
establish
use
mgkgday
day
recommend
seri
patient
receiv
therapi
recurr
infect
case
repeat
administr
immunoglobulin
recommend
monitor
treatment
respons
clinic
measl
viru
belong
morbilliviru
genu
within
paramyxovirida
famili
genom
consist
nonseg
rna
chain
neg
polar
encod
eight
protein
includ
envelop
glycoprotein
fusion
protein
f
haemagglutinin
h
import
pathogenesi
infect
incorpor
measl
vaccin
immunis
schedul
major
popul
contract
infect
childhood
given
eas
transmiss
viru
contact
nasal
throat
secret
infect
patient
result
lifelong
immun
world
health
organ
recognis
genotyp
viru
identifi
variabl
clinic
relev
affect
vaccin
efficaci
measl
viru
reappear
recent
year
affect
healthi
immunocompromis
patient
patient
contract
infect
present
symptom
fever
cough
runni
nose
coupl
presenc
characterist
rash
may
complic
pneumonia
enceph
even
system
dissemin
infect
sot
recipi
infect
also
link
present
acut
reject
diagnosi
choic
base
determin
specif
igm
antibodi
viru
seroconvers
igg
presenc
viral
genom
detect
use
rtpcr
throat
swab
urin
peripher
blood
typic
techniqu
perform
laboratori
epidemiolog
surveil
network
accredit
pretranspl
serolog
screen
recommend
order
administ
vaccin
necessari
case
erythroviru
infect
specif
antivir
treatment
instead
administr
immunoglobulin
postexposur
prophylaxi
recommend
unimmunis
patient
viru
aetiolog
agent
progress
multifoc
leukoencephalopathi
pml
diseas
caus
lytic
destruct
glial
cell
mainli
oligodendrocyt
affect
serious
immunosuppress
subject
fatal
case
largest
number
case
diseas
report
connect
human
immunodefici
viru
infect
develop
highli
effect
antiretrovir
therapi
sot
recipi
case
pml
report
renal
hepat
cardiac
pulmonari
transplant
patient
although
earli
case
occur
year
transplant
gener
middleag
elderli
individu
organ
transplant
dysfunct
due
recurr
underli
diseas
develop
reject
episod
requir
addit
immunosuppress
import
rememb
recent
year
case
pml
report
patient
autoimmun
diseas
treat
monoclon
antibodi
natalizumab
efalizumab
rituximab
rituximab
sometim
use
treatment
humor
reject
renal
transplant
patient
clinic
perspect
pml
may
present
vari
combin
neurolog
manifest
motor
sensori
disord
visual
field
disord
cognit
dysfunct
aphasia
instabl
gait
disord
multipl
lesion
often
observ
magnet
reson
imag
subcort
white
matter
cerebellar
peduncl
produc
oedema
trap
contrast
agent
show
mass
effect
presenc
characterist
radiolog
lesion
along
posit
pcr
detect
viru
dna
cerebrospin
fluid
csf
usual
consid
suffici
confirm
diagnosi
howev
nonneglig
percentag
case
detect
genet
materi
csf
neg
case
cerebr
biopsi
requir
diagnosi
truli
effect
antivir
therapi
jc
viru
signific
therapeut
measur
drastic
reduct
immunosuppress
sot
measur
especi
feasibl
renal
transplant
sinc
possibl
patient
return
haemodialysi
programm
therapeut
success
recent
report
use
mirtazapin
serotonerg
receptor
blocker
receptor
rout
entri
cell
jc
viru
isol
clinic
case
favour
outcom
report
clinic
trial
develop
use
antimalari
drug
mefloquin
treatment
human
infect
occur
almost
univers
asymptomat
first
decad
life
result
latent
infect
establish
urinari
system
excret
urin
may
occasion
detect
healthi
subject
renal
transplant
recipi
group
activ
infect
viru
usual
detect
although
activ
infect
occasion
report
type
sot
characterist
clinic
pictur
infect
renal
transplant
bk
polyomaviru
nephropathi
follow
risk
factor
nephropathi
report
cadaver
donor
ischaemiareperfus
damag
hla
donorrecipi
incompat
reject
episod
treatment
cumul
dose
steroid
drug
caus
deplet
lymphocyt
high
level
immunosuppress
drug
treatment
tacrolimu
versu
perform
cyclosporin
mtor
inhibitor
initi
infect
may
progress
asymptomat
may
detect
presenc
decoy
cell
epitheli
cell
characterist
intranuclear
inclus
urin
high
level
viruria
defin
excret
log
geqml
presenc
viraemia
detect
bk
dna
patient
blood
sampl
later
stage
nephropathi
usual
manifest
elev
serum
creatinin
diagnost
confirm
requir
biopsi
transplant
kidney
characterist
intranuclear
inclus
observ
tubular
epithelium
pariet
cell
glomerulu
lesion
accompani
variabl
degre
inflamm
fibrosi
tubular
atrophi
import
rememb
need
differenti
diagnosi
bk
nephropathi
nephropathi
caus
graft
reject
may
present
clinic
even
histolog
similar
correspond
therapeut
approach
complet
opposit
treatment
bk
viru
nephropathi
base
mainli
reduct
patient
immunosuppress
stimul
immun
respons
viru
variou
immunosuppress
reduct
regimen
suggest
monitor
treatment
respons
perform
use
measur
serum
creatinin
level
viraemia
viruria
event
persist
infect
variou
altern
suggest
date
none
studi
conclus
favour
one
altern
includ
use
cidofovir
leflunomid
intraven
immunoglobulin
quinolon
current
prophylact
approach
advoc
infect
use
period
measur
viruria
presenc
decoy
cell
urin
monthli
measur
recommend
first
three
month
quarterli
month
elaps
sinc
transplant
posit
cytolog
detect
log
geqml
indic
determin
viraemia
plasma
dna
level
greater
log
three
week
indic
presumpt
diagnosi
nephropathi
due
viru
case
physician
may
choos
confirm
biopsi
transplant
kidney
directli
reduct
immunosuppress
therapi
studi
suggest
period
monitor
directli
blood
may
use
recent
research
demonstr
protect
role
quinolon
develop
bk
viru
nephropathi
although
conflict
experi
publish
recent
studi
suggest
favour
prognosi
patient
receiv
new
renal
transplant
failur
previou
kidney
due
bk
polyomaviru
nephropathi
especi
viraemia
elimin
new
transplant
